Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Royalty Pharma Plc Cl A (NQ: RPRX ) 28.49 +0.32 (+1.14%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Royalty Pharma Plc Cl A < Previous 1 2 3 4 Next > Expert Ratings for Royalty Pharma August 08, 2022 Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings: Via Benzinga Royalty Pharma: Q2 Earnings Insights August 04, 2022 Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures July 14, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests July 13, 2022 Via Benzinga Warren Buffett Stocks: Royalty Pharma plc July 08, 2022 As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail. Via Talk Markets Expert Ratings for Royalty Pharma June 14, 2022 Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter: Via Benzinga Executives Sell Around $325M Of 3 Stocks May 24, 2022 Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. Via Benzinga Expert Ratings for Royalty Pharma May 13, 2022 Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter: Via Benzinga This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' June 30, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 June 14, 2022 Upgrades Via Benzinga Management of Technology Companies Continue Selling - Zillow (Z) May 31, 2022 In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of... Via Benzinga Royalty Pharma: Q1 Earnings Insights May 05, 2022 Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Recap: Royalty Pharma Q1 Earnings May 05, 2022 Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Royalty Pharma Earnings Perspective: Return On Capital Employed May 27, 2022 Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters. Via Benzinga Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple May 16, 2022 Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come. Via Investor's Business Daily Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022 May 13, 2022 Upgrades Via Benzinga How To Attend Royalty Pharma Q1 2022 Earnings Conference Call May 03, 2022 Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 April 14, 2022 Upgrades Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 April 06, 2022 Upgrades Via Benzinga Expedia And 3 Other Stocks Insiders Are Selling March 31, 2022 Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... Via Benzinga Hopeful Golden Cross Forms On Royalty Pharma's Chart March 01, 2022 If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,... Via Benzinga Looking Into Royalty Pharma's Return On Capital Employed February 16, 2022 According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%... Via Benzinga The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics February 15, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... Via Benzinga ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal January 18, 2022 ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital... Via Benzinga DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger January 18, 2022 Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney. Via InvestorPlace Earnings Scheduled For February 15, 2022 February 15, 2022 Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. Via Benzinga 2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again? January 09, 2022 The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market... Via Benzinga Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More December 10, 2021 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE: Via Benzinga BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo November 22, 2021 Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals... Via Benzinga Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know November 16, 2021 Warren Buffet's Berkshire Hathaway added more than 13 million shares. Via Investor's Business Daily < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.